Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00728481 · ClinicalTrials.gov registry record · Phase 2
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
A Phase 2 study of Eosinophilic Esophagitis and Gastroesophageal Reflux Disease, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT00728481 is a Phase 2 study of Eosinophilic Esophagitis and Gastroesophageal Reflux Disease that has completed, run by Mayo Clinic. The registered enrollment target is 51 participants, below the 863-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00728481, a Phase 2 study of Eosinophilic Esophagitis and Gastroesophageal Reflux Disease, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this study was to determine the proportion of patients with esophageal eosinophilic infiltration that have objective (measurable) evidence of gastroesophageal reflux disease (GERD). This study was also done to see if patients that have eosinophilic esophagitis (EE) and GERD would receive relief from taking the medication Nexium or a steroid called Pulmicort. The study also evaluated the accuracy of pH monitoring (acid exposure) within the esophagus as a predictor of endoscopic, histological and symptomatic response in patients with EE.
Conditions Studied
Interventions
- DRUG Esomeprazole
- DRUG Budesonide
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00728481
The ClinicalTrials.gov registry entry for NCT00728481 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 863-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (94% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which Esomeprazole is the first listed.
NCT00728481 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00728481 about?
NCT00728481 is a clinical study titled "The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis". The primary aim of this study was to determine the proportion of patients with esophageal eosinophilic infiltration that have objective (measurable) evidence of gastroesophageal reflux disease (GERD). This study was also done to see if patients that have eosinophilic esophagitis (EE) and GERD would...
What is the current status of trial NCT00728481?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2008-05. Estimated completion is 2010-12.
What conditions does trial NCT00728481 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, GERD, EE.
What interventions are being tested in trial NCT00728481?
The interventions under investigation include: Esomeprazole (DRUG), Budesonide (DRUG).
Who is sponsoring clinical trial NCT00728481?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00728481 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
RECRUITING · Phase 2
-
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
RECRUITING · Phase 2
-
Zemaira Eosinophilic Esophagitis Pilot Study
RECRUITING · Phase 2
-
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
COMPLETED · Phase 2
-
A Study of Flovent in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.